Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H101 + programmed death receptor-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Shanghai Sunway Biotech
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intrapleural, Intravenous
01
Overview
This combination therapy consists of the oncolytic adenovirus H101 (also known as Oncorine) and an unspecified programmed death receptor-1 (PD-1) inhibitor. It is currently being evaluated in a clinical trial (NCT06031636) sponsored by Tianjin Medical University Second Hospital for the treatment of advanced malignant pleural mesothelioma, specifically in patients who have previously shown resistance to PD-1 inhibitor monotherapy. H101 is a recombinant human adenovirus type 5 with deletions in the E1B-55K and E3 regions, designed to selectively replicate in and lyse p53-deficient tumor cells. The combination aims to reverse immune resistance by using the oncolytic virus to induce immunogenic cell death and alter the tumor microenvironment, thereby enhancing the efficacy of the PD-1 checkpoint inhibitor.
- Brand names
- Oncorine
- Other names
- recombinant human adenovirus type 5Oncolytic Adenovirus H101
02
Targets
CD47 (Cluster of Differentiation 47)PDCD1 (Programmed cell death protein 1 receptor)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on H101 + programmed death receptor-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H101 + programmed death receptor-1 inhibitor.